Fezolinetant
As of the edition of 20 October 2026, Fezolinetant is a small molecule: marketed, first approved in 2023 (US); acts on TACR3; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Veozah
- First approved
- 12 May 2023 (US)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Astellas; 3 holders in all
- Registered trials
- 30, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Hormones; Inherited and neonatal; Mental health; Nervous system
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Astellas.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Fezolinetant.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR3 | Neuromedin-K receptor | P29371 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 1 | 0 |
| Phase 1 | 7 | 6 | 1 | 0 |
| Phase 2 | 8 | 4 | 3 | 1 |
| Phase 3 | 12 | 8 | 4 | 0 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Originator, Applicant and Lead sponsor of trials | 2017 to now |